by TractManager | Jun 29, 2021 | Health Technology Assessment
Focus of the Report: This report focuses on the use of radiofrequency ablation (RFA) for treatment of symptomatic benign thyroid nodules (BTNs) in adult patients.Technology Description: RFA is an ultrasound (US)-guided, minimally invasive treatment approach, which...
by TractManager | Jun 28, 2021 | News
On June 25, 2021, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Actemra (tocilizumab; Genentech Inc.) for the treatment of hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic...
by TractManager | Jun 23, 2021 | Health Technology Assessment
Focus of the Report: This report focuses on annular closure for the prevention of recurrent lumbar disc herniation (LDH) after lumbar discectomy (LD).Technology Description: Annular closure is a surgical treatment that is performed immediately following an LDH...
by TractManager | Jun 9, 2021 | Emerging Technology Report
Ryplazim is plasma-derived human plasminogen indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). Ryplazim is recovered from healthy donor plasma; plasminogen is extracted using a proprietary process. Purified isolated...
by TractManager | Jun 7, 2021 | News
Today the Food and Drug Administration (FDA) approved a biologics license application (BLA) for Aduhelm (aducanumab; Biogen) for the treatment of Alzheimer disease. Aduhelm is an amyloid beta-directed antibody that is administered via intravenous infusion every 4...
Recent Comments